ATLANTA, January 20 /PRNewswire/ --

CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the development of innovative medical devices, today announced breakthrough results from the ATLANTA study of the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F at the 20th Annual International Symposium on Endovascular Therapy (ISET).

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU002 )

LONDON, January 19 /PRNewswire/ -- Saturday 19th January 2008 is The Great British Light Switch. In just 24 hours over two million people will receive a twin-pack of energy-saving lights free from Southern Electric.

These lights will potentially cut total CO2 emissions by over 350,000 tonnes and save Britons up to GBP20.25million per year on energy bills. Changing all the lights in the average home means households could save up to GBP600 over the bulbs' lifetime.

"The Great British Light Switch campaign is a moment in time when people can act together and make a real difference to cutting carbon emissions," commented Nic Frances, CEO, Cool nrg.

LONDON, January 18 /PRNewswire/ --

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel anti-inflammatory drugs, today announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).

MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with a NAC. The protocol was double-blinded and placebo-controlled. During the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.

ATLANTA, January 18 /PRNewswire/ --

Elekta, a world leader in clinical solutions for radiation therapy and radiosurgery, announced today that two sites are utilizing Elekta technology to implement clinical treatments with Volumetric Modulated Arc Therapy (VMAT)(i). With the recent CE designation of VMAT in Europe, the way has been cleared for The Royal Marsden Hospital in Sutton, UK and General Hospital Vienna in Austria to treat cancer using Elekta's VMAT solution.

BARCELONA, Spain, January 18 /PRNewswire/ --

- Centre seeks solutions to challenges and opportunities coming with multi-core processors.